Zum Inhalt springen

Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer

LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) — Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting. Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting

Recce Pharmaceuticals Granted New Patent in China

SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives

Novant Health und Michael Jordan arbeiten zusammen

Novant Health mit Sitz in Winston-Salem, North Carolina, hat sich mit dem ehemaligen Profi-Basketballspieler Michael Jordan zusammengetan, um eine neue medizinische Klinik zu eröffnen. Laut einer Pressemitteilung von Novant vom 7. Mai wurde die neue 7.800 Quadratmeter große Klinik mit dem Namen Novant Health Michael Jordan Family Medical Clinic in Wilmington, North Carolina, der Heimatstadt… Novant Health und Michael Jordan arbeiten zusammen, um den Zugang zur Gesundheitsversorgung zu erweitern

Filigree mesh: the new absorbable stent. Copyright: Karin Kaiser / MHH

MHH Cardiology implants self-dissolving stents

High-Tech Cardiology Made in Lower Saxony. Constricted coronary arteries harbor dangers: Because the heart is not supplied with blood properly, this can lead to pain, cardiac arrhythmia, cardiac insufficiency and sudden cardiac death. One way of eliminating a constriction in a vessel is to implant a stent. This involves the minimally invasive insertion of a small mesh tube into the vessel. Until now, all stents were made of metal and remained in the body, sometimes for decades, depending on the age of the patient. This has various disadvantages, but until now seemed unavoidable. Self-dissolving stents are therefore a groundbreaking innovation. The Department of Cardiology and Angiology at Hannover Medical School (MHH) is at the forefront of this field. A new type of absorbable stent from Biotronik has now been implanted in a patient there. It was the second implantation of… 

more »MHH Cardiology implants self-dissolving stents
Jan Wolter urges universities and laboratories to be vigilant. Credits: Jan Wolter

Labs Need Military Grade Cyber Security

Jan Wolter is one of Germany’s most prominent security experts. In the past, he has worked closely with the leading security agencies BSI, BKA, BND and BfV in the field of cyber and espionage defense to protect the German economy. Today, Wolter is an authorized representative of the DGKL Executive Committee. As part of the NACHGEFRAGT series, he answered important questions – and warns us to be vigilant in view of the current cyber threat situation. DGKL News: Mr. Wolter, do you actually stock up on medication? Wolter: I follow the recommendations of the Federal Office of Civil Protection and Disaster Assistance and always try to be sufficiently stocked. DGKL News: Of course, we asked this question for a reason. In Western Canada, a number of pharmacies in the London Drug chain are still shut down after the company fell victim to a cyber attack. How… 

more »Labs Need Military Grade Cyber Security

Radiotheranostika : Revolutionäre Krebstherapie

Forschende der Universität Zürich (UZH) entwickeln neue Krebstherapeutika. Die sogenannten Radiotheranostika sollen Tumore gleichzeitig lokalisieren und eliminieren können. Das Projekt wird unter dem Namen SMARTDrugs vom Europäischen Innovationsrat mit knapp 4 Millionen Euro gefördert. Forschende der Universität Zürich (UZH) entwickeln mit vier weiteren europäischen Teams eine neue Spezies von Medikamenten, die bei besonders […] UZH forscht an neuer Krebstherapie

LockBit hackt Deutsche Telekom

Strafverfolger scheinen erneut erneut eine Aktion gegen die Webseiten der Ransomware-Gruppe LockBit gefahren zu haben, um deren Server zu beschlagnahmen und die Operationen zu stoppen. Das berichtet das Fachportal Borncity.com.  „Andererseits gibt es wohl neue Ankündigungen von LockBit, die in den letzten Stunden um die 40 neue Opfer reklamieren. Eines der Opfer soll die Deutsche Telekom sein, deren Daten man ab dem 21. Mai 2024 veröffentlichen will“. LockBit 3.0 zurück? Gruppe reklamiert Angriff auf die Deutsche Telekom; Neue Beschlagnahmung

Breaking News: Vogelgrippe H5N1. Credits: LabNews Media LLC

Mabwell gets  Orphan Drug Designation for 9MW2821

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer. 9MW2821 was previously given Fast Track Designation (FTD) by the FDA for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma. It is the first therapeutic drug candidate targeting Nectin-4 in the world to reveal clinical effectiveness data for an esophageal cancer indication. 9MW2821 is the first site-specific conjugated novel Nectin-4-targeting ADC developed by Mabwell using ADC platform and automated high-throughput hybridoma antibody molecular discovery platform, and is the first drug candidate to enter clinical study among the Nectin-4-targeting ADCs developed by Chinese companies. Multiple clinical studies of 9MW2821 have been conducted in China to evaluate the… 

more »Mabwell gets  Orphan Drug Designation for 9MW2821

AI predicts tumor-killing cells

Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies. Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be applied to personalized cancer treatments that tailor therapy to the unique cellular makeup of each patient’s tumors. “The implementation of artificial intelligence in cellular therapy is new and may be a game-changer, offering new clinical options to patients,” said Ludwig Lausanne’s Alexandre Harari, who led the study with graduate student Rémy Pétremand. Home https://www.nature.com/articles/s41587-024-02232-0

Hot Water Potential Solution to Prostate Cancer

A clinical trial tests if hot water vapor can attack cancer cells, in new non-surgical approach to prostate cancer treatment. LAGUNA HILLS, Calif., May 7, 2024 /- MemorialCare Cancer Institute at Saddleback Medical Center is the only location in Orange County – and one of only two in California – to offer a new, innovative way to treat prostate cancer patients with water vapor. This study, VAPOR 2, utilizes a minimally invasive and nonsurgical procedure that employs water vapor to target and destroy the walls of the cancer cells while minimizing damage to the surrounding healthy prostate tissue. With the VAPOR 2 study, water vapor technology applies the thermal energy stored in a few drops of sterile water through a transurethral procedure – entering through the urethra – to get directly to the cancerous tissue. The heat from the water… 

more »Hot Water Potential Solution to Prostate Cancer